Roche's Announcement Regarding divarasib (Presentation of Latest Data in KRAS G12C-Positive Non-Small Cell Lung Cancer at ESMO)

TOKYO, October 26, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a media release on October 25 regarding the results of the Phase III Krascendo1 study of the KRAS G12C inhibitor divarasib in previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC), presented at the European Society for Medical Oncology Congress 2026 (ESMO 2026).

Please refer to the link below for details of Roche's media release:
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
https://www.roche.com/media/releases/med-cor-2026-10-25

Trademarks used or mentioned in this release are protected by laws.